| Literature DB >> 27595645 |
Sayako Morikawa1, Takuya Okamura1, Tomoyuki Minezawa1, Yasuhiro Goto1, Masamichi Hayashi1, Teppei Yamaguchi1, Sumito Isogai1, Yuki Mieno1, Naoki Yamamoto2, Sakurako Uozu1, Toru Nakanishi1, Mitsushi Okazawa3, Kazuyoshi Imaizumi4.
Abstract
BACKGROUND: Bronchial occlusion with an Endobronchial Watanabe Spigot (EWS) has been shown to be useful in managing prolonged bronchopleural fistulas and intractable hemoptysis. EWS bronchial occlusion using a curette is less technically demanding. This retrospective study evaluated the clinical utility and simplicity of this method.Entities:
Keywords: Endobronchial Watanabe Spigot; bronchial occlusion; bronchopleural fistula; bronchoscopy; curette
Mesh:
Substances:
Year: 2016 PMID: 27595645 PMCID: PMC5933595 DOI: 10.1177/1753465816664862
Source DB: PubMed Journal: Ther Adv Respir Dis ISSN: 1753-4658 Impact factor: 4.031
Figure 1.Photographs showing the method of EWS insertion using a cytology curette.
(A) A small cut was made with an 18-gauge injection needle at the thick end of the EWS to allow insertion of the tip of the curette. The tapered tip of a cytology curette could be inserted into the cut made on the tip of the EWS. (B) A curette equipped with an EWS could be rotated in any direction and bent at any angle. (C, D) Once the target bronchus was reached, the EWS was inserted into the bronchus, adjusting the angle and direction of the spigot. (E) After the EWS blocked the target bronchus, the curette was withdrawn while the EWS was pressed into the target bronchus with the bronchoscope.
Demographic and clinical characteristics of the included patients.
| Number of patients | (Number of EWSs inserted) | 18 (62) |
| Sex | Male | 15 |
| Female | 3 | |
| Age, years | Median (range) | 69 (47–85) |
| Target disease of EWS | Intractable pneumothorax | 11 |
| Postoperative bronchopleural fistula | 5 | |
| Recurrent hemoptysis | 1 | |
| Empyema | 1 | |
| Underlying diseases | Lung cancer | 6 |
| Aspergilloma | 5 | |
| COPD | 2 | |
| Pulmonary fibrosis | 2 | |
| Non-tuberculous mycobacteriosis | 2 | |
| CPFE | 1 |
COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; EWS, Endobronchial Watanabe Spigot.
Target bronchi and mean procedure time per patient.
| Patient number | Age (years) | Sex | Disease | Target bronchi | Number of EWS | Mean procedure time (min:s) |
|---|---|---|---|---|---|---|
|
| 81 | M | Pneumothorax | Rt B6, B8ab, B9a | 4 | 2:53 |
|
| 70 | F | Pneumothorax | Lt B1+2c, B3a | 2 | 2:54 |
|
| 77 | M | Pneumothorax | Rt B3a,b | 4 | 2:35 |
|
| 47 | M | Pneumothorax | Rt B5 | 1 | 4:28 |
|
| 72 | M | Hemoptysis | Lt B1+2a,b | 2 | 6:05 |
|
| 68 | M | Empyema | Lt B1+2b, B3a | 2 | 3:34 |
|
| 60 | M | Fistula | Lt B1+2a,b, B3b,c | 4 | 4:28 |
|
| 61 | M | Fistula | Lt B3a | 2 | 2:52 |
|
| 69 | M | Pneumothorax | Rt B1a,b, B2b, B3a | 7 | 1:33 |
|
| 50 | F | Fistula | Rt B2a,b | 4 | 1:32 |
|
| 85 | F | Pneumothorax | Rt B9a,b | 2 | 1:39 |
|
| 74 | M | Pneumothorax | Rt B1a,b | 6 | 3:57 |
|
| 59 | M | Pneumothorax | Lt B6a,b, B8a,b | 4 | 2:57 |
|
| 85 | M | Pneumothorax | Rt B1b, B2, B3b | 4 | 5:07 |
|
| 62 | M | Pneumothorax | Lt B1+2a,b, B3a,b | 5 | 1:56 |
|
| 63 | M | Fistula | Rt B1a, B2 | 3 | 1:43 |
|
| 63 | M | Fistula | Rt B2 | 1 | 3:39 |
|
| 61 | M | Pneumothorax | Rt B1b, B2 | 5 | 2:36 |
EWS, Endobronchial Watanabe Spigot; F, female; Fistula, postoperative bronchopleural fistula; Lt, left; M, male; Rt, right.
Figure 2.Time from the insertion of the bronchoscope into the endobronchial tube until successful insertion of an EWS into the target bronchus during each procedure. Of the 62 procedures, 36 (58.1%) were completed within 3 min, and 58 (93.5%) within 5 min.
Outcomes of each procedure.
| Underlying disease | Result | Post-EWS treatment | Complication | Outcome | |
|---|---|---|---|---|---|
|
| Lung cancer | Success | Pleurodesis | Drainage tube removed | |
|
| Pulmonary fibrosis | Success | Pleurodesis | Drainage tube removed | |
|
| COPD | Success | Pleurodesis | Drainage tube removed | |
|
| Lung cancer | Success | Pleurodesis | Drainage tube removed | |
|
| Lung cancer | Success | Hemoptysis stopped | ||
|
| Aspergilloma | Success | Myocardial infarction | Drainage tube removed | |
|
| Aspergilloma | Success | Drainage tube removed | ||
|
| Aspergilloma | Success | Drainage tube removed | ||
|
| CPFE | Success | Pleurodesis | Obstructive pneumonia | Drainage tube removed |
|
| Aspergilloma | Failure | Re-EWS | Prolonged drainage | |
|
| NTM | Success | Drainage tube removed | ||
|
| Pulmonary fibrosis | Failure | Pleurodesis | Death from AE | |
|
| Lung cancer | Failure | Pleurodesis | Cancer death | |
|
| NTM | Failure | Death from sepsis | ||
|
| COPD | Success | Pleurodesis | Drainage tube removed | |
|
| Lung cancer | Failure | Re-EWS | Prolonged drainage | |
|
| Lung cancer | Success | Cancer death | ||
|
| Aspergilloma[ | Success | Pleurodesis | Arrhythmia | Drainage tube removed |
Recurrences in patients 7 and 8.
AE, acute exacerbation; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; EWS, Endobronchial Watanabe Spigot; fistula, postoperative bronchopleural fistula; NTM, nontuberculous mycobacteriosis; PSVT, paroxysmal supraventricular tachycardia.